MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $17.40 and traded as low as $16.05. MediWound shares last traded at $16.29, with a volume of 28,922 shares changing hands.
Analyst Upgrades and Downgrades
MDWD has been the topic of several analyst reports. StockNews.com upgraded shares of MediWound to a "sell" rating in a research note on Friday, March 21st. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of MediWound in a research note on Thursday, March 20th.
Read Our Latest Stock Report on MDWD
MediWound Stock Performance
The business's 50 day moving average price is $16.91 and its two-hundred day moving average price is $17.41. The company has a market capitalization of $194.00 million, a price-to-earnings ratio of -6.19 and a beta of 0.50.
MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period in the prior year, the firm posted ($0.19) earnings per share. On average, sell-side analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Yelin Lapidot Holdings Management Ltd. boosted its position in shares of MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company's stock valued at $15,154,000 after purchasing an additional 100,618 shares in the last quarter. Northern Trust Corp lifted its stake in MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock valued at $2,577,000 after purchasing an additional 70,367 shares during the last quarter. State Street Corp boosted its holdings in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock worth $1,197,000 after buying an additional 45,529 shares in the last quarter. Essex Investment Management Co. LLC grew its position in MediWound by 30.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock worth $2,651,000 after buying an additional 35,012 shares during the last quarter. Finally, MGO One Seven LLC bought a new position in shares of MediWound in the fourth quarter valued at $216,000. 46.83% of the stock is owned by institutional investors and hedge funds.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Further Reading
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
